Karyopharm Therapeutics Inc. reports developments tied to its commercial oncology business and selinexor-based drug development. The company markets XPOVIO (selinexor) and reports U.S. product revenue, license and other revenue, liquidity, and operating updates alongside its periodic financial results.
Recurring KPTI news also covers late-stage clinical programs evaluating selinexor in cancer indications, including the Phase 3 SENTRY trial in myelofibrosis and the Phase 3 XPORT-EC-042 trial in endometrial cancer. Company updates include clinical data presentations, regulatory-development disclosures, equity inducement grants under Nasdaq rules, financing activity, and other corporate and capital-structure matters.
Karyopharm Therapeutics (Nasdaq: KPTI) will host a virtual Investor Day on December 8, 2021, from 10:00 a.m. to 12:30 p.m. ET. The event will feature Karyopharm's executive team and six experts in oncology to discuss commercial opportunities and pipeline priorities. Attendees can join via phone or view a live webcast on the company’s website. Karyopharm specializes in cancer therapies, notably its lead drug XPOVIO®, approved for several hematologic cancers. The event aims to outline the company's vision and milestones.
Karyopharm Therapeutics (Nasdaq: KPTI) announced participation in the Jefferies London Healthcare Conference with CEO Richard Paulson hosting a fireside chat. The discussion will be available for on-demand listening starting November 18, 2021, at 3:00 a.m. Eastern Time. A replay will be accessible for 30 days on the company's investor website.
Karyopharm is focused on developing innovative cancer therapies, particularly through its XPOVIO® (selinexor) compound, which is approved for multiple hematologic malignancies.
Karyopharm Therapeutics (KPTI) announced new data from a Phase 2 study of selinexor, an oral SINE compound for myelofibrosis patients previously treated with JAK inhibitors. The study showed a 33% response rate, with significant spleen volume reduction and improved anemia status. Despite ruxolitinib's poor prognosis (14 months survival), selinexor demonstrated durable responses and a well-tolerated safety profile. Karyopharm plans to initiate a new Phase 2 study evaluating selinexor against physician's choice in late 2021. Results will be presented at the ASH 2021 meeting from December 11-14.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) reported third-quarter 2021 financial results, revealing net product revenue of $26.7 million, a 32% increase from the previous quarter and 25% growth year-over-year. The company highlighted its commercial success with XPOVIO, moving into earlier treatment lines for multiple myeloma. R&D expenses rose to $45.8 million, while the net loss was $51.8 million or $0.69 per share. Karyopharm expects a cash runway into mid-2023, with key upcoming milestones including Phase 3 data from the SIENDO study in endometrial cancer.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the granting of stock options for 171,300 shares to 15 newly-hired employees as of October 29, 2021. This grant, compliant with Nasdaq Listing Rule 5635(c)(4), includes a stock option exercise price of $5.46 per share. The options vest over four years, with 25% vesting at the one-year mark. In instances of a "change in control event," the options are immediately exercisable if employment is terminated for "good reason" or without "cause." Karyopharm specializes in innovative cancer therapies, notably its lead compound, XPOVIO®.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its third quarter 2021 financial results on November 3, 2021. The company's management will host a conference call at 8:30 a.m. ET on the same day to discuss results and updates. Karyopharm focuses on innovative cancer therapies, notably its lead compound, XPOVIO® (selinexor), which is approved for multiple hematologic malignancies in the U.S. and has received conditional authorization in Europe. For details, visit the investor section.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that the first patient has been dosed in the Phase 2 expansion study evaluating eltanexor for myelodysplastic syndrome (MDS). This follows promising Phase 1 results showing a 53% overall response rate and a median overall survival of 9.9 months in high-risk, relapsed MDS patients. The Phase 2 expansion aims to assess eltanexor monotherapy in HMA-refractory MDS patients, with the overall response rate as the primary endpoint. Eltanexor is part of a new approach targeting nuclear export to treat various cancers.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the grant of stock options to 21 newly-hired employees as an inducement for joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). A total of 147,300 shares were awarded, with an exercise price of $5.82 per share, reflecting the stock's closing price on September 30, 2021. The options vest over four years, with a portion becoming immediately exercisable under specific conditions related to employment termination. Karyopharm specializes in pioneering cancer therapies, including its lead compound, XPOVIO®.
On September 7, 2021, Karyopharm Therapeutics (Nasdaq: KPTI) announced its CEO, Richard Paulson, will present at three virtual investor conferences in September. The presentations include:
- H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 AM ET (podium presentation).
- Morgan Stanley 19th Annual Global Healthcare Conference on September 13 at 11:00 AM ET (fireside chat).
- Baird 2021 Global Healthcare Conference on September 14 at 2:00 PM ET (fireside chat).
Karyopharm Therapeutics (NASDAQ: KPTI) announced the granting of stock options as inducements for new hires, including Senior VP Eleonora Goldberg, totaling 100,000 shares for her and 76,700 shares for 16 other new employees. These stock options, with an exercise price of $5.80 per share, vest over four years, with some options becoming immediately exercisable under specific conditions. The company focuses on pioneering cancer therapies, particularly through its SINE compounds, which target nuclear export in cancer treatment and show promise in various diseases.